Compare Phillips 66 (PSX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs 10X Genomics Inc — how do they compare? Phillips 66 trades at $211.8 (market cap $85.11B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Phillips 66 is far larger — about 15.5× 10X Genomics Inc's market cap, and Phillips 66 pays a 2.39% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| PSX | TXG | |
|---|---|---|
Market Cap | $85.11B | $5.48B |
Sector | Energy | Health |
52-Week High | $212.27 | $47.20 |
52-Week Low | $118.37 | $11.34 |
Enterprise Value | $107.08B | $5.02B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $212.27, up 2.62% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026's positive surprise, highlight operational strength amid volatile energy markets. The stock benefits from robust refining margins and disciplined capital returns, including a $1.27 quarterly dividend. Valuation metrics like a P/E of 20.63 and P/S of 0.63 suggest relative affordability compared to sector peers.
Outlook remains positive due to tight fuel markets and efficient refining operations, though risks include oil price volatility and declining revenue trends. With 57% of analysts rating it a buy and a consensus price target of $201.50, the stock offers upside potential, but investors should monitor debt levels and macroeconomic pressures on energy demand.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
